3 Papers
Ryan Sun is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Triple-negative breast cancer & Neoadjuvant therapy. The author has an hindex of 3, co-authored 3 publications.
Chat about Author
Papers
A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer.
Clinton Yam,Gaiane M. Rauch,Tanbin Rahman,Meghan Sri Karuturi,Elizabeth Ravenberg,Jason B White,Alyson Clayborn,Pamela McCarthy,Sausan Abouharb,Bora Lim,Jennifer K. Litton,David Ramirez,Sadia Saleem,James Stec,W. Fraser Symmans,Lei Huo,Senthil Damodaran,Ryan Sun,Stacy L. Moulder +18 more
TL;DR: Treatment with mirvetuximab-s should only be further explored in TNBC if an alternate biomarker strategy is developed for patient selection on the basis of additional preclinical data, and the observed rate of FRα positivity was considerably lower than previously reported.
23
Implementation of a novel web-based lesion selection tool to improve acquisition of tumor biopsy specimens
Mingxuan Xu,Coya Tapia,Joud Hajjar,Sharjeel H. Sabir,Rivka R. Colen,Priyadharsini Nagarajan,Phyu P. Aung,Jing Gong,Jordi Rodon,Siqing Fu,Bettzy Stephen,Sinchita Roy-Chowdhuri,Hung Le,Vincent Yang,Abdulrazzak Zarifa,Mohamed Abdelsalam,Anuja Jhingran,Milind Javle,Shubham Pant,Brett W. Carter,Denái R. Milton,Ryan Sun,Daniel D. Karp,Eugene J. Koay,Yali Yang,Ignacio I. Wistuba,Patrick Hwu,Funda Meric-Bernstam,Aung Naing +28 more
- 01 May 2021
TL;DR: A web-based lesion selection tool (LST) that enables management and tracking of the biopsy specimen collections and enables sampling of the designated lesion consistently, which is likely to accurately inform us the effect of the treatment on tumor microenvironment and evolution of resistant pathways.
Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.
Clinton Yam,Er-Yen Yen,Jeffrey T. Chang,Roland L. Bassett,Gheath Alatrash,Haven R. Garber,Lei Huo,Fei Yang,Anne V. Philips,Qingqing Ding,Bora Lim,Naoto T. Ueno,Kasthuri Kannan,Xiangjie Sun,Baohua Sun,Edwin Roger Parra Cuentas,William Fraser Symmans,Jason B White,Elizabeth Ravenberg,Sahil Seth,Jennifer L. Guerriero,Gaiane M. Rauch,Senthil Damodaran,Jennifer K. Litton,Jennifer A. Wargo,Gabriel N. Hortobagyi,Andrew Futreal,Ignacio I. Wistuba,Ryan Sun,Stacy L. Moulder,Elizabeth A. Mittendorf,Elizabeth A. Mittendorf +31 more
TL;DR: In this article, the authors investigated the effect of increasing tumor-infiltrating lymphocytes (TILs) on pathologic complete response (pCR) in patients with triple-negative breast cancer.